Growth Factors of Lymphoma Treatment Market
The global lymphoma treatment market was valued at USD 6.94 billion in 2018 and is projected tsurpass USD 21.29 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.3% during the forecast period.
Key Market Drivers:
- Increasing Prevalence of Lymphomas: A significant rise in lymphoma cases has heightened the demand for advanced treatment options. Many lymphomas remain asymptomatic until advanced stages, necessitating more aggressive therapies for effective outcomes.
- Advancements in Research and Development: Leading biopharmaceutical companies are investing heavily in R&D tdevelop novel therapies. For instance, Kura Oncology's clinical trial of tipifarnib for peripheral T-cell lymphoma, which received FDA fast track designation in March 2020, exemplifies this trend.
- North America: Dominated the market with a 47.98% share in 2018, attributed thigher lymphoma prevalence, greater patient awareness, and the adoption of advanced therapeutics.
- Europe and Asia-Pacific: Europe is expected tmaintain a significant market share, while Asia-Pacific is projected texperience the highest CAGR during the forecast period, driven by approvals of key drugs and a large potential patient population.
- Immunotherapy: Accounted for the largest market share in 2018 due tits success in achieving positive outcomes. Products like Yescarta by Kite Pharma, Inc. have been instrumental in this segment's dominance.
- Targeted Therapy and Chemotherapy: Targeted therapy holds the second-largest segment, owing tthe precision in targeting cancer cells. Chemotherapy remains a vital treatment option due tits established efficacy.
- High Treatment Costs: In emerging regions, the high cost of therapies, especially immunotherapies, limits patient access and adoption, posing a significant challenge tmarket growth.
ATTRIBUTE DETAILS
Study Period - 2015-2026
Base Year - 2018
Forecast Period - 2019-2026
Historical Period - 2015-2017
Unit - Value (USD billion)
Segmentation By Therapy
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Others
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)
- Latin America (Brazil, Mexico, and the Rest of Latin America)
- Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of Lymphoma - by Key Countries - 2018
- 4.2. Pipeline Analysis
- 4.3. Key Industry Developments
- 4.4. Regulatory Scenario, by Key Regions
- 4.5. Analysis of Economic Burden of Lymphoma
- 4.6. New Product Launches
- 4.7. Overview of Emerging Treatments for Lymphoma
- 5. Global Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Therapy
- 5.2.1. Immunotherapy
- 5.2.2. Targeted Therapy
- 5.2.3. Chemotherapy
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast – By Disease Type
- 5.3.1. Non-Hodgkin Lymphoma
- 5.3.2. Hodgkin Lymphoma
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Retail Pharmacies & Drug Stores
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
- 6.1. Key Findings / Summary
- 6.2. Market Analysis – By Therapy
- 6.2.1. Immunotherapy
- 6.2.2. Targeted Therapy
- 6.2.3. Chemotherapy
- 6.2.4. Others
- 6.3. Market Analysis – By Disease Type
- 6.3.1. Non-Hodgkin Lymphoma
- 6.3.2. Hodgkin Lymphoma
- 6.4. Market Analysis – By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Retail Pharmacies & Drug Stores
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. Europe Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
- 7.1. Key Findings / Summary
- 7.2. Market Analysis – By Therapy
- 7.2.1. Immunotherapy
- 7.2.2. Targeted Therapy
- 7.2.3. Chemotherapy
- 7.2.4. Others
- 7.3. Market Analysis – By Disease Type
- 7.3.1. Non-Hodgkin Lymphoma
- 7.3.2. Hodgkin Lymphoma
- 7.4. Market Analysis – By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Retail Pharmacies & Drug Stores
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis – By Country/ sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
- 8. Asia Pacific Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
- 8.1. Key Findings / Summary
- 8.2. Market Analysis – By Therapy
- 8.2.1. Immunotherapy
- 8.2.2. Targeted Therapy
- 8.2.3. Chemotherapy
- 8.2.4. Others
- 8.3. Market Analysis – By Disease Type
- 8.3.1. Non-Hodgkin Lymphoma
- 8.3.2. Hodgkin Lymphoma
- 8.4. Market Analysis – By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Retail Pharmacies & Drug Stores
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis – By Country/ sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
- 9. Latin America Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
- 9.1. Key Findings / Summary
- 9.2. Market Analysis – By Therapy
- 9.2.1. Immunotherapy
- 9.2.2. Targeted Therapy
- 9.2.3. Chemotherapy
- 9.2.4. Others
- 9.3. Market Analysis – By Disease Type
- 9.3.1. Non-Hodgkin Lymphoma
- 9.3.2. Hodgkin Lymphoma
- 9.4. Market Analysis – By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Retail Pharmacies & Drug Stores
- 9.4.3. Online Pharmacies
- 9.5. Market Analysis – By Country/ sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
- 10. Middle East & Africa Lymphoma Treatment Market Analysis, Insights and Forecast, 2015-2026
- 10.1. Key Findings / Summary
- 10.2. Market Analysis – By Therapy
- 10.2.1. Immunotherapy
- 10.2.2. Targeted Therapy
- 10.2.3. Chemotherapy
- 10.2.4. Others
- 10.3. Market Analysis – By Disease Type
- 10.3.1. Non-Hodgkin Lymphoma
- 10.3.2. Hodgkin Lymphoma
- 10.4. Market Analysis – By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies & Drug Stores
- 10.4.3. Online Pharmacies
- 10.5. Market Analysis – By Country/ sub-region
- 10.5.1. GCC Countries
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2018)
- 11.3. Competition Dashboard
- 11.4. Comparative Analysis – Major Players
- 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.5.1. Takeda Pharmaceutical Company Limited
- 11.5.1.1. Overview,
- 11.5.1.2. Products & services,
- 11.5.1.3. SWOT analysis,
- 11.5.1.4. Recent developments,
- 11.5.1.5. strategies,
- 11.5.1.6. financials (based on availability)
- 11.5.2. AstraZeneca
- 11.5.2.1. Overview,
- 11.5.2.2. Products & services,
- 11.5.2.3. SWOT analysis,
- 11.5.2.4. Recent developments,
- 11.5.2.5. strategies,
- 11.5.2.6. financials (based on availability)
- 11.5.3. Bayer AG
- 11.5.3.1. Overview,
- 11.5.3.2. Products & services,
- 11.5.3.3. SWOT analysis,
- 11.5.3.4. Recent developments,
- 11.5.3.5. strategies,
- 11.5.3.6. financials (based on availability)
- 11.5.4. Novartis AG
- 11.5.4.1. Overview,
- 11.5.4.2. Products & services,
- 11.5.4.3. SWOT analysis,
- 11.5.4.4. Recent developments,
- 11.5.4.5. strategies,
- 11.5.4.6. financials (based on availability)
- 11.5.5. Spectrum Pharmaceuticals, Inc.
- 11.5.5.1. Overview,
- 11.5.5.2. Products & services,
- 11.5.5.3. SWOT analysis,
- 11.5.5.4. Recent developments,
- 11.5.5.5. strategies,
- 11.5.5.6. financials (based on availability)
- 11.5.6. Bristol Myers Squibb Company
- 11.5.6.1. Overview,
- 11.5.6.2. Products & services,
- 11.5.6.3. SWOT analysis,
- 11.5.6.4. Recent developments,
- 11.5.6.5. strategies,
- 11.5.6.6. financials (based on availability)
- 11.5.7. Janssen Pharmaceuticals, Inc.
- 11.5.7.1. Overview,
- 11.5.7.2. Products & services,
- 11.5.7.3. SWOT analysis,
- 11.5.7.4. Recent developments,
- 11.5.7.5. strategies,
- 11.5.7.6. financials (based on availability)
- 11.5.8. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
- 11.5.8.1. Overview,
- 11.5.8.2. Products & services,
- 11.5.8.3. SWOT analysis,
- 11.5.8.4. Recent developments,
- 11.5.8.5. strategies,
- 11.5.8.6. financials (based on availability)
- 11.5.9. Merck & Co., Inc.
- 11.5.9.1. Overview,
- 11.5.9.2. Products & services,
- 11.5.9.3. SWOT analysis,
- 11.5.9.4. Recent developments,
- 11.5.9.5. strategies,
- 11.5.9.6. financials (based on availability)
- 11.5.10. Spectrum Pharmaceuticals, Inc.
- 11.5.10.1. Overview,
- 11.5.10.2. Products & services,
- 11.5.10.3. SWOT analysis,
- 11.5.10.4. Recent developments,
- 11.5.10.5. strategies,
- 11.5.10.6. financials (based on availability)
- 11.5.11. Other Prominent Players
- 11.5.11.1. Overview,
- 11.5.11.2. Products & services,
- 11.5.11.3. SWOT analysis,
- 11.5.11.4. Recent developments,
- 11.5.11.5. strategies,
- 11.5.11.6. financials (based on availability)
- 12. Strategic Recommendations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook